Basilea has announced this morning that sales of its antifungal Cresemba in the Asia Pacific region have exceeded the sales threshold required, resulting in a $5m milestone payment from licensee Pfizer. With Cresemba facing loss of exclusivity in the US and Europe from Q4 2027, sales outside of these regions become signficantly more important, particularly in potentially large markets like China and Japan where Cresemba is still relatively early in its commercial roll out. Nevertheless,...

Basilea announced this morning it has entered into a collaboration with privately held US anti-infectives specialist Prokaryotics to jointly develop a first-in-class broad spectrum antifungal for the treatment of severe invasive fungal infections. Under the terms of the agreement, Basilea will make an undisclosed upfront as well as near term milestone payments. Following the selection of a clinical candidate, Basilea will undertake clinical development and commercialisation. Prokaryotics is...

Basilea announced the receipt of a $30 million milestone payment this morning, as its leading antifungal, Cresemba, exceeded the predetermined sales threshold in Europe. The receipt of this significant sales milestone from European licensee Pfizer is a testament to the continued strong growth of Cresemba, despite its maturity, and thanks to its profile, which combines a broad spectrum with a favourable side-effect profile. Efforts at Basilea to prepare for the loss of exclusivity for Cresemba...